Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30066159 | 1.00 | S1PR1 (0.41) | S1PR1S1PR3S1PR4S1PR5NOTUM | |
| SCHEMBL3906129 | 0.98 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5NOTUM | |
| SCHEMBL31435310 | 0.97 | NOTUM (0.40) | S1PR1S1PR3S1PR4S1PR5NOTUM | |
| SCHEMBL3897505 | 0.97 | NOTUM (0.40) | S1PR1S1PR3S1PR4S1PR5NOTUM | |
| SCHEMBL3901815 | 0.93 | NOTUM (0.44) | S1PR1S1PR3S1PR4S1PR5NOTUM | |
| SCHEMBL2231906 | 0.87 | NOTUM (0.40) | S1PR1S1PR3NOTUMHTR2C | |
| SCHEMBL2235318 | 0.87 | S1PR1 (0.43) | S1PR1S1PR3S1PR4S1PR5NOTUM | |
| SCHEMBL22074016 | 0.84 | S1PR1 (0.41) | S1PR1S1PR3S1PR4S1PR5NOTUM | |
| SCHEMBL31195718 | 0.84 | S1PR1 (0.43) | S1PR1S1PR3S1PR4S1PR5NOTUM | |
| SCHEMBL16152104 | 0.84 | S1PR1 (0.43) | S1PR1S1PR3S1PR4S1PR5NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3378854-B1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARM INC (US) | 2022-12-21 | — | — | EP | claimed |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | claimed |
| EP-3378854-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2018-09-26 | — | — | EP | claimed |
| CN-103221391-B | Preparation method of (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl) acetic acid and salt thereof | 艾尼纳制药公司 | 2018-07-06 | — | — | CN | claimed |
| US-9175320-B2 | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | claimed |
| US-20140357690-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | claimed |
| CN-103221391-A | Preparation method of -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl) acetic acid and salt thereof | ARENA PHARM INC | 2013-07-24 | — | — | CN | claimed |
| EP-2528894-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2012-12-05 | — | — | EP | claimed |
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | claimed |
| WO-2011094008-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | claimed |
| EP-4685237-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF ETRASIMOD AND RELATED COMPOUNDS | CURIA SPAIN, S.A.U. (ES) | 2026-01-28 | — | — | EP | disclosed |
| US-12486229-B2 | Indole derivative and application thereof | SHANGHAI MEDICILON INC. (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20230357148-A1 | INDOLE DERIVATIVE AND APPLICATION THEREOF | SHANGHAI MEDICILON INC. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 4/4885S1PR4 5/4885 |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | S1PR3, S1PR2, S1PR1 | S1PR1 3/4885S1PR3 1/4885S1PR4 6/4885 |
| US-20230357148-A1 | INDOLE DERIVATIVE AND APPLICATION THEREOF | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885S1PR4 6/4885 |
| US-12486229-B2 | Indole derivative and application thereof | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885S1PR4 6/4885 |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 5/4885 |
| US-20140357690-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 4/4885S1PR4 5/4885 |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 5/4885 |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 4/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.